Patent SG-11201810371X-A (SG)
Title: ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
Inventor: DEMATTOS RONALD BRADLEY
IPC: A61P25/28
Filed: 2017-06-23
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 011111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/005282 Al 04 January 2018 (04.01.2018) W I PO I PCT (51) International Patent Classification: Declarations under Rule 4.17: C07K 16/18 (2006.01) A61P 25/28 (2006.01) A61K 39/395 (2006.01) — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) (21) International Application Number: — as to the applicant's entitlement to claim the priority of the PCT/US2017/038999 earlier application (Rule 4.17(iii)) (22) International Filing Date: Published: 23 June 2017 (23.06.2017) — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/357,579 01 July 2016 (01.07.2016) US (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). (72) Inventors: DEMATTOS, Ronald Bradley; c/o ELI LIL- LY AND COMPANY, P.O. Box 6288, Indianapolis, Indi- ana 46206-6288 (US). IRIZARRY, Michael Carl; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, In- diana 46206-6288 (US). — = Agent: JIVRAJ, Sanjay M. et al.; ELI LILLY AND COM- (74) _ PANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 = (US). Designated States (unless otherwise indicated, for every = (81) kind of national protection available): AE, AG, AL, AM, = _ AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = = SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = — 1-1 ei GC N kr) 0 C:::: ) (54) Title: ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF --.... ,-1 (57) : The invention is directed to a short term induction treatment with anti-N3pGlu AO antibodies of a disease characterized 0 by deposition of AO in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). \" In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu AO antibody for a period 0 of 6 months or less.